Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NEO logo NEO
Upturn stock ratingUpturn stock rating
NEO logo

NeoGenomics Inc (NEO)

Upturn stock ratingUpturn stock rating
$7.18
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: NEO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

14 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $11.25

1 Year Target Price $11.25

Analysts Price Target For last 52 week
$11.25Target price
Low$6.08
Current$7.18
high$19.11

Analysis of Past Performance

Type Stock
Historic Profit -28.59%
Avg. Invested days 39
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 940.76M USD
Price to earnings Ratio -
1Y Target Price 11.25
Price to earnings Ratio -
1Y Target Price 11.25
Volume (30-day avg) 14
Beta 1.64
52 Weeks Range 6.08 - 19.11
Updated Date 06/30/2025
52 Weeks Range 6.08 - 19.11
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.61

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -11.54%
Operating Margin (TTM) -16.56%

Management Effectiveness

Return on Assets (TTM) -2.75%
Return on Equity (TTM) -8.57%

Valuation

Trailing PE -
Forward PE 222.22
Enterprise Value 1170727531
Price to Sales(TTM) 1.4
Enterprise Value 1170727531
Price to Sales(TTM) 1.4
Enterprise Value to Revenue 1.74
Enterprise Value to EBITDA -27.92
Shares Outstanding 128695000
Shares Floating 120342230
Shares Outstanding 128695000
Shares Floating 120342230
Percent Insiders 1.19
Percent Institutions 100.73

Analyst Ratings

Rating 4
Target Price 11.25
Buy 2
Strong Buy 6
Buy 2
Strong Buy 6
Hold 6
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

NeoGenomics Inc

stock logo

Company Overview

overview logo History and Background

NeoGenomics Inc. was founded in 2001. It has grown through acquisitions and organic growth to become a leading cancer testing and information services company.

business area logo Core Business Areas

  • Pharma Services: Provides comprehensive testing and pathology services to pharmaceutical companies to support drug development and clinical trials.
  • Clinical Services: Offers a range of cancer diagnostic, prognostic, and predictive testing services to community-based pathologists and oncologists. This includes tests like FISH, cytogenetics, flow cytometry, IHC and molecular tests (e.g. next generation sequencing).

leadership logo Leadership and Structure

The leadership team includes Chris Smith (CEO), Dr. Maher Albitar (Chief Medical Officer), and other key executives. The company is structured around its clinical and pharma services divisions.

Top Products and Market Share

overview logo Key Offerings

  • Next Generation Sequencing (NGS) Panels: Comprehensive NGS panels for various cancers. NeoGenomics does not publicly report exact market share numbers for NGS panels, but is a leading provider in this area, competing with companies like Foundation Medicine (part of Roche). Revenue from Clinical services account for bulk of company's revenue.
  • Fluorescence In Situ Hybridization (FISH) Testing: FISH testing for various cancers. No specific market share data available for NeoGenomics, but is one of the services that drive revenue. Competition includes LabCorp.
  • IHC Testing: NeoGenomics provides a variety of IHC tests. No specific market share data available for NeoGenomics.

Market Dynamics

industry overview logo Industry Overview

The cancer diagnostics market is growing due to increasing cancer incidence, advancements in technology, and demand for personalized medicine.

Positioning

NeoGenomics Inc is positioned as a key player in the cancer diagnostics market, particularly in specialized testing for oncologists, pathologists and biopharma. Key competitive advantages include its comprehensive test menu, expertise in oncology, and relationships with oncologists and pharma companies.

Total Addressable Market (TAM)

The global cancer diagnostics market size is expected to reach hundreds of billions of USD. NeoGenomics Inc is positioned to address a significant portion of this TAM, particularly within specialized oncology testing.

Upturn SWOT Analysis

Strengths

  • Comprehensive test menu
  • Strong relationships with oncologists
  • Expertise in oncology
  • Pharma services offerings

Weaknesses

  • Past inconsistent profitability
  • Reliance on reimbursement rates
  • Debt levels.

Opportunities

  • Expanding personalized medicine market
  • Increasing demand for NGS
  • Partnerships with pharmaceutical companies
  • International expansion

Threats

  • Increased competition
  • Reimbursement rate pressures
  • Technological advancements by competitors
  • Economic downturns affecting testing volumes

Competitors and Market Share

competitor logo Key Competitors

  • LH
  • DGX
  • FMI

Competitive Landscape

NeoGenomics is a smaller player in the overall clinical lab market compared to LabCorp and Quest. Its focus on oncology testing provides a competitive advantage in that specific area.

Major Acquisitions

Clarient Diagnostics

  • Year: 2012
  • Acquisition Price (USD millions): 260
  • Strategic Rationale: Expanded NeoGenomics' presence in hematopathology and solid tumor testing.

Growth Trajectory and Initiatives

Historical Growth: NeoGenomics Inc has experienced significant revenue growth over the past decade, primarily driven by acquisitions and expansion in cancer testing services.

Future Projections: Future growth projections depend on factors such as market expansion, technological advancements, and competition. Analyst estimates should be consulted for specific financial forecasts.

Recent Initiatives: Recent initiatives include expansion of pharma services, investment in new technologies, and strategic partnerships.

Summary

NeoGenomics Inc. is a cancer testing company with a comprehensive test menu and strong relationships with oncologists. While they have experienced significant growth, past inconsistent profitability and increasing competition remain challenges. The expansion of the personalized medicine market and strategic partnerships offer opportunities for future growth. They are still a smaller company than their competitors in the overall clinical lab market.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on source.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About NeoGenomics Inc

Exchange NASDAQ
Headquaters Fort Myers, FL, United States
IPO Launch date 1999-11-02
CEO & Director Mr. Anthony P. Zook
Sector Healthcare
Industry Diagnostics & Research
Full time employees 2200
Full time employees 2200

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.